Supporting Information

EnantiodivergentSynthesisof1,2-Bis(diphenylphosphino)ethanesviaAsymmetric[3+2]-cycloaddition

Bing Liu, Wenbo Li, Haihong Wu, and Junliang Zhang*

Table Contents

1.	General Information	S3
2.	Table S1. Screening the Known Ligands ^[a]	S4
3.	Table S2. Optimization of Reaction Conditions for (-)-3a [a]	S5
4.	General Procedure for the Synthesis of products 3-13	S5
5.	References	
6.	¹ H, ³¹ P, ¹³ C NMR and HPLC Spectra	

1. General Information

All reactions were carried out under an atmosphere of nitrogen in flame-dried glassware with magnetic stirring. ¹H NMR spectra, ¹⁹F NMR spectra, ¹³C NMR spectra were recorded on a Bruker 300, 400 and 500 MHz spectrometer in CDCl₃. All signals are reported in ppm with the internal TMS signal at 0 ppm as a standard. Data for ¹H NMR spectra are reported as follows: chemical shift (ppm, referenced to TMS; s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, coupling constant(s) in Hz, integration), coupling constant (Hz), and intergration. Data for ¹³C NMR are reported in terms of chemical shift (ppm) relative to residual solvent peak (CDCl₃: 77.0 ppm). Reactions were monitored by thin layer chromatography (TLC) using silica gel plates. Flash column chromatography was performed over silica gel (300-400 mesh). THF, Et₂O and MTBE were freshly distilled from sodium metal prior to use. The ligands L2-L13 were synthesized according to the procedure of reference.¹ Other known ligands were commercially available. The substrate **1a** were synthesized according to the procedure of references.³

2. Table S1. Screening the Known Ligands^[a]

R ¹ [∼] N [∼] CO ₂ Me	1a Cu(CH ₃ CN) ₄ PF ₆ (20 mol%) Ligand (21 mol%)	Ph ₂ OP POPh ₂ Ph	POPh ₂
$R^1 = 4$ -BrPh	Cs ₂ CO ₃ (50 mol%)	R ¹ CO ₂ Me	R ¹ CO ₂ Me
2	CHCl ₃ /Et ₂ O, rt	x	(-)-3
Entry	Ligand	Yield (%) ^[b]	$Ee (\%)^{[c]}(X/(-)-3)$
1	L6	100% conv.	-/42
2	L7	100% conv.	51/27
3	L8	trace	-
4	L9	80% conv.	42/15
5	L10	100% conv.	25/31
6	L11	100% conv.	30/18
7	L12	trace	-
8	L13	23% conv.	-/16
Me P-h Me	Me Ph O P-N Me Naphthyl	Me. Naphth	yl Me. yl OrP-N Me Ph
L5 , (<i>R</i> , <i>S</i> , <i>S</i>) 100% Conv., /42% ee	L6 , (S,R,R) 100% conv., 51/27% ee	L7 , (<i>R</i> , <i>R</i> , <i>R</i>), trace	L8 , <i>(S,R,R)</i> 80% conv., 42/15% ee
Bn Or P-N Bn			SiMe ₃ O, P-N Me SiMe ₃
L9 , <i>(R)</i> 100% conv., 25/31% ee	L10 , <i>(R)</i> 100% conv., 30/18% ee	L11, (R), trace	L12 , (<i>R</i> , <i>S</i> , <i>S</i>) 23% conv., /16% ee

[a] All reactions were carried out with 0.025 mmol of 1a, 0.2 mmol of 2a, 20 mol% of catalyst ([Cu] to Ligand = 1:1.05), 50 mol% Cs₂CO₃ in 1.5 ml Solvent (CHCl₃/Et₂O = 1) at rt for 24 h. [b] NMR yield with CH₂Br₂ as an internal standard. [c] Determined by chiral HPLC.

	$R^{1} N CO_{2}Me - Ce$ $R^{1} = 4-BrPh CF$ 2	1a [Cu] 5 mol% (S,R,R)-L4 № № № Ph ₂ OF № № № № № № № № № № № № №	POPh ₂ N CO ₂ Me (-)-3	G Me G Me (S,R,R)-L4, G = 3,5-(CF ₃)	Ph Ph J₂C6H3
Entry	[Cu]	Solvent	Dr ^[b] (X/(-)-3)	Yield (%) ^[c]	<i>Ee</i> (%) ^[d]
1	Cu(CH ₃ CN) ₄ BF ₄	$CHCl_3/Et_2O = 1$		30% conv.	95%
2	Cu(CH ₃ CN) ₄ NTf ₂	$CHCl_3/Et_2O = 1$		50% conv.	98%
3	Cu(CH ₃ CN) ₄ ClO ₄	$CHCl_3/Et_2O = 1$		60% conv.	99%
4	Cu(CH ₃ CN) ₄ PF ₆	$CHCl_3/Et_2O = 1$	1:13	100% conv.	>99%
5	Cu(CH ₃ CN) ₄ PF ₆	$CHCl_3/THF = 1$		Trace	
6	Cu(CH ₃ CN) ₄ PF ₆	$CHCl_3/MTBE = 1$		40% conv.	97%

3. Table S2. Optimization of Reaction Conditions for (-)-3a [a]

[a] All reactions were carried out with 0.025 mmol of **1a**, 0.2 mmol of **2a**, 20 mol% of catalyst ([Cu] to Ligand = 1:1.05), 50% Cs₂CO₃ in 1.5 ml Solvent at -10 °C for 24 h. [b] The diastereomeric ratios were determined by ¹H, ³¹P NMR analysis of the crude products. [c] NMR yield with CH_2Br_2 as an internal standard. [d] Determined by chiral HPLC.

4. General Procedure for the Synthesis of products 3-13

Typical procedure for asymmetric copper-catalyzed cycloaddition of alkene with glycine ketoimino ester.

The solution of Ligand (21.0 mol%) and Cu(CH₃CN)₄PF₆ (20 mol%) in CHCl₃/Et₂O = 1:1 (6 mL) was stirred at room temperature for 1 h. After the reaction temperature was dropped to -10 °C, azomethine ylides **2** (0.2 mmol), Cs₂CO₃ (0.05 mmol) and alkene **1** (0.1 mmol) were added sequentially. After the alkene **1** was consumed completely, remove the solvent under reduced pressure. The crude product was analyzed with ¹H NMR and ³¹P NMR to determine the diastereomeric ratio. Then the crude product was purified by flash column chromatography on silica gel to afford the desired product. The enantionmeric excesses of the products were determined by chiral stationary phase HPLC.

Conditions A: using (S, R, R)-L4 as the ligand. **Conditions B:** using (R, R, R)-L4 as the ligand.



1. Synthesis of (-)-3a and (+)-3a.

Under conditions A: The reaction of alkene 1a (42.8 mg, 0.1 mmol) and glycine imino ester 2a (51.0 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-3a as a white solid (58.7 mg, 86% yield) with 14:1 dr and 99% *ee*. mp: 220-221 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.74 (t, J = 8.7 Hz, 2H), 7.44 -7.36 (m, 8H), 7.33-7.26 (m, 6H), 7.23-7.12 (m, 8H), 4.45-4.34 (m, 2H), 3.76 (d, J =10.2 Hz, 1H), 3.49-3.43 (m, 1H), 3.27 (s, 1H), 2.88 (s, 3H). ³¹P NMR (162 MHz, CDCl₃) δ 33.37 (d, J = 30.4 Hz), 33.13 (d, J = 30.5 Hz). ¹³C NMR (101 MHz, CDCl₃) δ 168.47 (d, J = 3.6 Hz), 139.70 (d, J = 2.2 Hz), 131.86, 131.41, 131.30, 131.28, 131.19, 130.51 (d, J = 8.1 Hz), 130.32 (d, J = 8.3 Hz), 129.99, 128.69 (t, J = 9.0 Hz), 128.27 (t, J =11.2 Hz), 121.64, 65.15, 63.04, 51.09, 46.71 (dt, J = 31.2, 17.5 Hz), 42.04 (dt, J = 63.7, 16.1 Hz). ESI-MS calculated for C₃₆H₃₃BrNO₄P₂: m/z (%): 684.1063 (M+H⁺), found: 684.1066. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 18.0 min, minor enantiomer tr = 42.6 min. [α]_D²⁵ = -16.4 (c = 0.25, CHCl₃).



Under conditions B: the product (+)-**3a** was obtained as a white solid (54.6 mg, 80% yield) with 11:1 dr and 99% *ee.* mp: 191-192 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 41.5 min, minor enantiomer tr = 17.6 min. $[\alpha]_D^{25} = +21.2$ (c = 0.25, CHCl₃).



2. Synthesis of (-)-3b and (+)-3b.

Under conditions A: The reaction of alkene 1a (42.8 mg, 0.1 mmol) and glycine imino ester 2b (51.0 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-3b as a white solid (60.1 mg, 88% yield) with >20:1 dr and 96% *ee*. mp: 231-232 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.61-8.59 (m, 1H), 7.75 (t, J = 9.0 Hz, 2H), 7.53-7.38 (m, 10H), 7.33-7.23 (m, 4H), 7.19-7.05 (m, 7H), 5.04 (s, 1H), 4.44 (d, J = 23.4 Hz, 1H), 3.89-3.81 (m, 2H), 3.13 (s, 1H), 2.90 (s, 3H). ³¹P NMR (202 MHz, CDCl₃) δ 33.67. ¹³C NMR (126 MHz, CDCl₃) δ 168.48, 139.62, 132.22, 131.73, 131.50 (dd, J = 6.1, 3.0 Hz), 131.28, 130.99 (dd, J = 6.3, 2.9 Hz), 130.47 (dd, J = 5.9, 2.6 Hz), 130.32 (dd, J = 6.2, 2.7 Hz), 129.66, 129.12, 128.73-128.40 (m), 128.28, 128.21-127.87 (m), 125.85, 65.23, 61.14, 51.09, 46.12 (dt, J = 39.4, 13.4 Hz), 41.90 (dt, J = 34.2, 12.6 Hz). ESI-MS calculated for C₃₆H₃₃BrNO₄P₂: m/z (%): 684.1063 (M+H⁺), found: 684.1065. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 65:45 to 45:65, 0.8 mL/min, 230 nm); major enantiomer tr = 13.1 min, minor enantiomer tr = 76.0 min. [α]p²⁵ = -5.6 (*c* = 0.25, CHCl₃).





Under conditions B: the product (+)-**3b** was obtained as a white solid (60.7 mg, 89% yield) with >20:1 dr and 99% *ee.* mp: 236-237 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 65:45 to 45:65, 0.8 mL/min, 230 nm); major enantiomer tr = 75.2 min, minor enantiomer tr = 14.0 min. $[\alpha]_D^{25} = +5.2$ (*c* = 0.25, CHCl₃).



3. Synthesis of (-)-3c and (+)-3c.

Under conditions A: The reaction of alkene **1a** (42.8 mg, 0.1 mmol) and glycine imino ester **2c** (51.0 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-**3c** as a white solid (60.1 mg, 88% yield) with 14:1 dr and 98% *ee.* mp: 115-116 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.70 (s, 2H), 7.51 (d, *J* = 6.6 Hz, 1H), 7.36 -7.26 (m, 11H), 7.24-7.19 (m, 4H), 7.11-7.05 (m, 5H), 6.98 (s, 1H), 4.38 (d, *J* = 23.0 Hz, 1H), 4.26 (d, *J* = 9.1 Hz, 1H), 3.72 (d, *J* = 13.5 Hz, 1H), 3.39 (d, *J* = 14.8 Hz, 1H), 3.26 (s, 1H), 2.85 (s, 3H). ³¹P NMR (162 MHz, CDCl₃) δ 33.15 (q, *J* = 30.7 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 168.61 (d, *J* = 4.1 Hz), 142.97 (d, *J* = 2.7 Hz), 132.34 (d, *J* = 2.1 Hz), 131.97 (d, *J* = 2.0 Hz), 131.66 (d, *J* = 2.1 Hz), 131.58, 131.55, 131.36 (t, *J* = 7.9 Hz), 128.39 (t, *J* = 10.4 Hz), 126.58, 122.11, 63.18, 51.22, 47.13 (dd, *J* = 59.4, 5.1 Hz), 42.10 (dd, *J* = 58.2, 7.2 Hz). ESI-MS calculated for C₃₆H₃₃BrNO₄P₂: m/z (%): 684.1063 (M+H⁺), found: 684.1057. Enantiomeric excess was determined by

HPLC with a Chiralpak IA column (hexanes: 2-propanol = 70:30, 0.8 mL/min, 230 nm); major enantiomer tr = 23.2 min, minor enantiomer tr = 32.0 min. $[\alpha]_D^{25} = -14.4$ (*c* = 0.25, CHCl₃).



Under conditions B: the product (+)-**3c** was obtained as a white solid (64.8 mg, 95% yield) with >20:1 dr and >99% *ee.* mp: 121-122 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 70:30, 0.8 mL/min, 230 nm); major enantiomer tr = 29.2 min, minor enantiomer tr = 23.1 min. $[\alpha]_D^{25} = +13.2$ (c = 0.25, CHCl₃).



4. Synthesis of (-)-3d and (+)-3d.

Under conditions A: The reaction of alkene **1a** (42.8 mg, 0.1 mmol) and glycine imino ester **2d** (39.0 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-**3d** as a white solid (56.7 mg, 91% yield) with 19:1 dr and >99% *ee.* mp: 212-213 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.79-7.74 (m, 2H), 7.50-7.35 (m, 10H), 7.34-7.28 (m, 4H), 7.23 (t, *J* = 6.9 Hz, 2H), 7.15 (t, *J* = 7.7 Hz, 4H), 6.85 (t, *J* = 8.7 Hz, 2H), 4.43 (d, *J* = 21.3 Hz, 2H), 3.83-3.76 (m, 1H), 3.57-3.50 (m,

1H), 3.26 (s, 1H), 2.91 (s, 3H). ¹⁹F NMR (282 MHz, CDCl₃) δ -114.53. ³¹P NMR (162 MHz, CDCl₃) δ 33.39 (d, J = 2.7 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 168.65, 162.30 (d, J = 246.3 Hz), 136.55, 131.96, 131.51, 131.44-131.25 (m), 130.76-130.59 (m), 130.59-130.34 (m), 130.10 (d, J = 8.1 Hz), 129.05-128.63 (m), 128.38 (dd, J = 11.8, 7.4 Hz), 115.38, 115.21, 65.24, 63.11, 51.24, 46.82 (dt, J = 38.6, 13.9 Hz), 42.16 (dt, J = 41.0, 12.6 Hz). ESI-MS calculated for C₃₆H₃₂FNNaO₄P₂: m/z (%): 646.1683 (M+Na⁺), found: 646.1680. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 8.1 min, minor enantiomer tr = 65.9 min. [α]_D²⁵ = -14.4 (c = 0.25, CHCl₃).



Under conditions B: the product (+)-**3d** was obtained as a white solid (54.2 mg, 87% yield) with >20:1 dr and 99% *ee.* mp: 203-204 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 62.8 min, minor enantiomer tr = 8.2 min. $[\alpha]_D^{25} = +14.4$ (*c* = 0.25, CHCl₃).



5. Synthesis of (-)-3e and (+)-3e.

Under conditions A: The reaction of alkene 1a (42.8 mg, 0.1 mmol) and glycine imino ester 2e (42.2 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-3e as a white solid (46.6 mg, 73% yield) with 15:1 dr and 99% *ee.* mp: 111-112 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.77-7.34 (m, 2H), 7.48-7.38 (m, 8H), 7.37 -7.29(m, 4H), 7.26-7.21 (m, 4H), 7.17-7.12 (m, 6H), 4.46-4.34 (m, 2H), 3.81-3.77 (m, 1H), 3.52-3.48 (m, 1H), 3.29 (s, 1H), 2.90 (s, 3H). ³¹P NMR (202 MHz, CDCl₃) δ 33.37, 33.34. ¹³C NMR (126 MHz, CDCl₃) δ 168.62 (d, *J* = 3.6 Hz), 139.30, 133.56, 132.00 (d, *J* = 2.7 Hz), 131.54, 131.50, 131.39 (d, *J* = 8.7 Hz), 130.68 (d, *J* = 8.4 Hz), 130.48 (d, *J* = 8.7 Hz), 129.79, 128.82 (dd, *J* = 11.4, 9.1 Hz), 128.61, 128.55-128.18 (m), 65.29, 63.12, 51.25, 46.85 (dt, *J* = 67.6, 16.2 Hz), 42.19 (dt, *J* = 34.0, 14.3 Hz). ESI-MS calculated for C₃₆H₃₂ClNNaO₄P₂: m/z (%): 662.1387 (M+Na⁺), found: 662.1385. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 16.9 min, minor enantiomer tr = 49.1 min. [α]₂²⁵ = -22.0 (*c* = 0.25, CHCl₃).



Under conditions B: the product (+)-**3e** was obtained as a white solid (55.0 mg, 86% yield) with >20:1 dr and 98% *ee.* mp: 97-98 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 48.5 min, minor enantiomer tr = 17.3 min. $[\alpha]_D^{25} = +20.0$ (*c* = 0.25, CHCl₃).



6. Synthesis of (-)-3f and (+)-3f.

Under conditions A: The reaction of alkene 1a (42.8 mg, 0.1 mmol) and glycine imino ester 2f (49.0 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-3f as a white solid (61.9 mg, 92% yield) with 13:1 dr and >99% *ee.* mp: 224-225 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.72-7.67 (m, 2H), 7.43-7.25 (m, 16H), 7.16-7.08 (m, 6H), 4.43-4.36 (m, 2H), 3.75-3.70 (m, 1H), 3.57-3.50 (m, 1H), 3.23 (s, 1H), 2.86 (s, 3H). ¹⁹F NMR (282 MHz, CDCl₃) δ -62.55. ³¹P NMR (162 MHz, CDCl₃) δ 33.14 (dd, *J* = 81.0, 30.1 Hz). ¹³C NMR (101 MHz, CDCl₃) δ 168.54 (d, *J* = 4.5 Hz), 144.77, 131.99 (dd, *J* = 5.3, 2.5 Hz), 131.66 (q, *J*_{C-F} = 281.4 Hz), 131.65, 131.56, 131.51, 131.31 (d, *J* = 8.7 Hz), 130.67 (d, *J* = 8.6 Hz), 130.48 (d, *J* = 8.8 Hz), 128.87, 128.76 (t, *J* = 5.6 Hz), 128.35 (t, *J* = 11.0 Hz), 125.31 (d, *J* = 3.8 Hz), 65.32, 63.08, 51.25, 46.76 (d, *J* = 64.4 Hz), 42.22 (d, *J* = 62.2 Hz). ESI-MS calculated for C₃₇H₃₂F₃NNaO₄P₂: m/z (%): 696.1651 (M+Na⁺), found: 696.1651. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 210 nm); major enantiomer tr = 7.5 min, minor enantiomer tr = 68.8 min. [α]_D²⁵ = -28.0 (*c* = 0.25, CHCl₃).





Under conditions B: the product (+)-**3f** was obtained as a white solid (57.2 mg, 85% yield) with 18:1 dr and 96% *ee.* mp: 197-198 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 65.5 min, minor enantiomer tr = 7.7 min. $[\alpha]_D^{25} = +31.6$ (*c* = 0.25, CHCl₃).



7. Synthesis of (-)-3g and (+)-3g.

Under conditions A: The reaction of alkene **1a** (42.8 mg, 0.1 mmol) and glycine imino ester **2g** (40.4 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-**3g** as a white solid (59.2 mg, 94% yield) with >20:1 dr and >99% *ee.* mp: 86-87 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.75-7.71 (m, 2H), 7.50-7.31 (m, 16H), 7.24-7.14 (m, 6H), 4.46 (d, *J* = 20.1 Hz, 2H), 3.77-3.72 (m, 1H), 3.61-3.55 (m, 1H), 3.27 (s, 1H), 2.91 (s, 3H). ³¹P NMR (202 MHz, CDCl₃) δ 33.16 (dd, *J* = 158.7, 30.1 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 168.45 (d, *J* = 4.6 Hz), 146.19 (d, *J* = 3.0 Hz), 132.23, 132.13 (dd, *J* = 9.5, 2.6 Hz), 131.64 (d, *J* = 9.2 Hz), 131.29 (d, *J* = 9.0 Hz), 131.47 (dd, *J* = 44.4, 9.1 Hz), 130.57 (dd, *J* = 21.5, 8.9 Hz), 129.21, 128.89 (dd, *J* = 11.5, 6.9 Hz), 128.45 (dd, *J* = 23.2, 11.6 Hz), 118.80, 115.66, 111.51, 65.27 (d, *J* = 3.0 Hz), 62.92, 51.32, 46.74 (d, *J* = 66.7 Hz), 42.21 (d, *J* = 65.3 Hz). ESI-MS calculated

for C₃₇H₃₂N₂NaO₄P₂: m/z (%): 653.1730 (M+Na⁺), found: 653.1737. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 210 nm); major enantiomer tr = 11.3 min, minor enantiomer tr = 76.9 min. $[\alpha]_D^{25}$ = -20.8 (*c* = 0.25, CHCl₃).



Under conditions B: the product (+)-**3g** was obtained as a white solid (60.5 mg, 96% yield) with >20:1 dr and >99% *ee.* mp: 93-94 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 53.9 min, minor enantiomer tr = 11.3 min. $[\alpha]_D^{25} = +24.8$ (*c* = 0.25, CHCl₃).



8. Synthesis of (-)-3h and (+)-3h.

Under conditions A: The reaction of alkene **1a** (42.8 mg, 0.1 mmol) and glycine imino ester **2h** (44.4 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-**3h** as a white solid (63.7 mg, 98% yield) with >20:1 dr and >99% *ee.* mp: 87-88 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.01 (d, *J* = 8.7 Hz, 2H), 7.78-7.74(m, 2H), 7.53-7.34 (m, 14H), 7.26-7.18 (m, 6H), 4.57-4.48 (m, 2H), 3.82-3.76

(m, 1H), 3.67-3.60 (m, 1H), 3.33 (s, 1H), 2.94 (s, 3H). ³¹P NMR (202 MHz, CDCl₃) δ 33.33 (dd, J = 157.7, 30.0 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 168.44 (d, J = 4.7 Hz), 147.40, 132.21 (d, J = 21.8 Hz), 131.70 (d, J = 9.3 Hz), 131.31 (d, J = 9.0 Hz), 130.69 (d, J = 8.8 Hz), 130.51 (d, J = 9.0 Hz), 128.92 (dd, J = 11.6, 6.8 Hz), 128.62 (d, J = 11.5 Hz), 128.39 (d, J = 11.8 Hz), 129.41, 123.57, 115.65, 65.28, 62.55, 51.37, 46.84 (d, J = 66.4 Hz), 42.28 (d, J = 65.2 Hz). ESI-MS calculated for C₃₆H₃₃N₂O₆P₂: m/z (%): 651.1808 (M+H⁺), found: 651.1812. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 65:35 to 50:50, 0.8 mL/min, 230 nm); major enantiomer tr = 11.7 min, minor enantiomer tr = 68.0 min. [α]_D²⁵ = -10.4 (c = 0.25, CHCl₃).



Under conditions B: the product (+)-**3h** was obtained as a white solid (59.2 mg, 91% yield) with >20:1 dr and 99% *ee.* mp: 116-117 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 65:35, 0.8 mL/min, 230 nm); major enantiomer tr = 68.2 min, minor enantiomer tr = 12.3 min. $[\alpha]_D^{25} = +8.0$ (*c* = 0.25, CHCl₃).



9. Synthesis of (-)-3i and (+)-3i.

Under conditions A: The reaction of alkene 1a (42.8 mg, 0.1 mmol) and glycine imino ester 2i (47.0 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-3i as a white solid (61.7 mg, 93% yield) with >20:1 dr and >99% *ee.* mp: 120-121 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.82 (d, *J* = 8.3 Hz, 2H), 7.77-7.73 (m, 2H), 7.49-7.29 (m, 14H), 7.20-7.12 (m, 6H), 4.48-4.41 (m, 2H), 3.89 (s, 3H), 3.82-3.77 (m, 1H), 3.55-3.49 (m, 1H), 3.35 (s, 1H), 2.90 (s, 3H). ³¹P NMR (202 MHz, CDCl₃) δ 33.36 (q, *J* = 30.3 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 168.60 (d, *J* = 4.1 Hz), 166.96, 145.75, 132.06 (d, *J* = 13.8 Hz), 131.53, 131.34 (d, *J* = 8.3 Hz), 130.71 (d, *J* = 8.0 Hz), 130.50 (d, *J* = 8.3 Hz), 129.77, 129.51, 128.84 (t, *J* = 10.6 Hz), 128.43 (dd, *J* = 15.3, 10.1 Hz), 128.40, 115.68, 65.39, 63.42, 52.14, 51.27, 46.93 (d, *J* = 64.5 Hz), 42.27 (d, *J* = 65.6 Hz). ESI-MS calculated for C₃₈H₃₅NNaO₆P₂: m/z (%): 686.1832 (M+Na⁺), found: 686.1839. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 65:35 to 45:55, 0.8 mL/min, 230 nm); major enantiomer tr = 10.0 min, minor enantiomer tr = 51.8 min. [α]_D²⁵ = -20.4 (*c* = 0.25, CHCl₃).



Under conditions B: the product (+)-**3i** was obtained as a white solid (61.0 mg, 92% yield) with >20:1 dr and 98% *ee.* mp: 111-112 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 65:35 to 45:55, 0.8 mL/min, 230 nm); major enantiomer tr = 50.8 min, minor enantiomer tr = 10.9 min. $[\alpha]_D^{25} = +24.4$ (*c* = 0.25, CHCl₃).



10. Synthesis of (-)-3j and (+)-3j.

Under conditions A: The reaction of alkene 1a (42.8 mg, 0.1 mmol) and glycine imino ester 2j (51.0 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-3j as a white solid (54.0 mg, 79% yield) with 7:1 dr and >99% ee. mp: 101-102 °C. ¹H NMR (500 MHz, CDCl₃) & 7.76-7.72 (m, 4H), 7.52 (d, J = 8.4 Hz, 2H), 7.49-7.33 (m, 12H), 7.23-7.14 (m, 4H), 4.51-4.44 (m, 2H), 3.79-3.73 (m, 1H), 3.55-3.49 (m, 1H), 3.33 (s, 1H), 3.01 (s, 3H), 2.90 (s, 3H). ³¹P NMR (202 MHz, CDCl₃) δ 33.98 (dd, J = 223.2, 33.7 Hz), 32.31 (dd, J = 178.8, 33.7 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 168.47 (d, J = 4.6 Hz), 147.12 (d, J = 3.1 Hz), 139.77, 132.19 (d, J = 21.6 Hz), 131.71, 131.55 (d, J = 9.0 Hz), 131.31 (d, J = 8.8 Hz), 130.56 (dd, J = 16.0, 8.9 Hz), 129.48, 128.94 (dd, J = 11.6, 4.4 Hz), 128.58 (d, J = 11.4 Hz), 128.40 (d, J = 11.6 Hz), 127.52, 65.35, 62.99, 51.30, 46.95 (d, J = 65.8 Hz), 44.49, 42.22 (d, J = 65.4 Hz). ESI-MS calculated for C₃₇H₃₅NNaO₆P₂S: m/z (%): 706.1553 (M+Na⁺), found: 706.1551. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 65:35 to 45:55, 0.8 mL/min, 230 nm); major enantiomer tr = 18.0 min, minor enantiomer tr = 80.2 min. $[\alpha]_D^{25}$ = -24.4 (c = 0.25, CHCl₃).





Under conditions B: the product (+)-**3j** was obtained as a white solid (54.6 mg, 80% yield) with 10:1 dr and 94% *ee*. mp: 96-97 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 65:35 to 45:55, 0.8 mL/min, 230 nm); major enantiomer tr = 80.0 min, minor enantiomer tr = 18.3 min. $[\alpha]_D^{25} = +22.8$ (*c* = 0.25, CHCl₃).



11. Synthesis of (-)-3k and (+)-3k.

Under conditions A: The reaction of alkene **1a** (42.8 mg, 0.1 mmol) and glycine imino ester **2k** (50.6 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-**3k** as a white solid (55.2 mg, 81% yield) with 10:1 dr and 94% *ee.* mp: 95-96 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.82-7.78 (m, 1H), 7.57 (d, J = 7.5 Hz, 1H), 7.50-7.29 (m, 8H), 7.22-7.15 (m, 3H), 4.74-4.32 (m, 2H), 4.09-3.80 (m, 1H), 3.62 (dd, J = 18.8, 5.2 Hz, 1H), 3.36 (s, 1H), 2.92 (s, 3H). ³¹P NMR (202 MHz, CDCl₃) δ 33.59 (q, J = 30.2 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 168.60, 140.71, 140.38, 131.81, 131.48, 131.40, 131.36, 131.34, 130.66 (d, J = 8.3 Hz), 130.42 (d, J = 8.5 Hz), 128.69, 128.67 (dd, J = 14.2, 6.4 Hz), 128.26 (dd, J = 11.1, 6.0 Hz), 127.22, 127.06, 126.92, 65.28, 63.51, 51.12, 46.76 (d, J = 64.5 Hz), 42.18 (d, J = 64.9 Hz). ESI-MS calculated for C₄₂H₃₈NO₄P₂: m/z (%): 682.2271 (M+Na⁺), found: 682.2254. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 20.9 min, minor

enantiomer tr = 45.5 min. $[\alpha]_D^{25}$ = -30.0 (*c* = 0.25, CHCl₃).



Under conditions B: the product (+)-**3k** was obtained as a white solid (42.2 mg, 62% yield) with 16:1 dr and 97% *ee.* mp: 110-111 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 42.3 min, minor enantiomer tr = 21.9 min. $[\alpha]_D^{25} = +32.8$ (*c* = 0.25, CHCl₃).



12. Synthesis of (-)-3l and (+)-3l.

Under conditions A: The reaction of alkene **1a** (42.8 mg, 0.1 mmol) and glycine imino ester **2l** (44.6 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-**3l** as a white solid (44.3 mg, 68% yield) with 10:1 dr and >99% *ee*. mp: 95-96 °C. ¹H NMR (300 MHz, CDCl₃) δ 7.82-7.76 (m, 2H), 7.51-7.34 (m, 12H), 7.29-7.19 (m, 8H), 7.09 (d, *J* = 8.0 Hz, 2H), 5.35 (s, 1H), 4.74-4.32 (m, 1H), 3.91 (d, *J* = 16.2 Hz, 1H), 3.49 (m, 1H), 2.93 (s, 3H), 2.47 (s, 3H). ³¹P NMR (122 MHz, CDCl₃) δ 33.69 (d, *J* = 109.2 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 167.12, 138.94, 132.12, 131.69, 131.33 (d, *J* = 9.1 Hz), 131.20 (d, *J* = 9.0 Hz), 130.43 (dd, *J* = 8.8, 6.2 Hz), 128.93, 128.82, 128.79, 128.48, 128.39, 126.45, 64.21, 62.68, 51.56, 15.56, 45.67

(d, J = 62.3 Hz), 40.97 (d, J = 66.8 Hz). ESI-MS calculated for C₃₇H₃₆NO₄P₂S: m/z (%): 652.1835 (M+H⁺), found: 652.1818. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 65:45 to 45:65, 0.8 mL/min, 210 nm); major enantiomer tr = 9.9 min, minor enantiomer tr = 56.1 min. [α]_D²⁵ = -77.1 (c= 0.25, CHCl₃).



Under conditions B: the product (+)-**31** was obtained as a white solid (52.7 mg, 81% yield) with 10:1 dr and 99% *ee*. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 65:45 to 45:65, 0.8 mL/min, 210 nm); major enantiomer tr = 49.0 min, minor enantiomer tr = 10.8 min. $[\alpha]_D^{25} = +63.4$ (*c* = 0.25, CHCl₃).



13. Synthesis of (-)-3m and (+)-3m.

Under conditions A: The reaction of alkene **1a** (42.8 mg, 0.1 mmol) and glycine imino ester **2m** (45.4 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-**3m** as a white solid (49.8 mg, 76% yield) with 6:1 dr and

99% *ee*. mp: 133-134 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.89-7.79 (m, 5H), 7.57-7.28 (m, 17H), 7.15-7.11 (m, 5H), 4.59-4.50 (m, 2H), 3.91 (d, J = 15.7 Hz, 1H), 3.61-3.56 (m, 1H), 3.40 (s, 1H), 2.93 (s, 3H). ³¹P NMR (202 MHz, CDCl₃) δ 33.63 (q, J = 30.4 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 168.67, 137.67, 132.87 (d, J = 4.3 Hz), 131.85, 131.40, 131.37, 130.48 (dd, J = 34.7, 8.3 Hz), 128.75, 128.67, 128.58, 128.49, 128.30, 128.21, 128.08, 127.80, 127.38, 125.83, 125.70, 125.32, 65.30, 64.00, 51.09, 46.68 (d, J = 58.1 Hz), 42.22 (d, J = 65.6 Hz). ESI-MS calculated for C₄₀H₃₅NNaO₄P₂: m/z (%): 678.1934 (M+Na⁺), found: 678.1943. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 10.3 min, minor enantiomer tr = 61.8 min. [α]_D²⁵ = -35.6 (c = 0.25, CHCl₃).





Under conditions B: the product (+)-**3m** was obtained as a white solid (41.3 mg, 63% yield) with 11:1 dr and 98% *ee*. mp: 128-129 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 58.6 min, minor enantiomer tr = 10.2 min. $[\alpha]_D^{25} = +31.6$ (*c* = 0.25, CHCl₃).



14. Synthesis of (-)-3n and (+)-3n.

Under conditions A: The reaction of alkene 1a (42.8 mg, 0.1 mmol) and glycine imino ester 2n (66.2 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-3n as a white solid (67.6 mg, 89% yield) with 15:1 dr and 95% *ee.* mp: 219-220 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.81-7.77 (m, 2H), 7.51-7.38 (m, 10H), 7.33-7.25 (m, 7H), 7.25-7.21 (m, 4H), 7.19-7.11 (m, 6H), 4.53-3.87 (m, 2H), 4.45-4.35 (m, 1H), 3.83-3.77 (m, 1H), 3.68-3.61 (m, 1H). ³¹P NMR (162 MHz, CDCl₃) δ 33.24 (q, J = 29.7 Hz). ¹³C NMR (101 MHz, CDCl₃) δ 168.08 (d, J = 4.3 Hz), 139.81 (d, J = 2.7 Hz), 134.81, 131.86, 131.71 (d, J = 8.6 Hz), 131.46, 131.40, 131.25 (d, J = 8.5 Hz), 130.65 (d, J = 8.1 Hz), 130.34 (d, J = 8.3 Hz), 130.08, 128.85-128.46 (m), 128.45-128.17 (m), 128.32, 128.10, 128.04, 121.68, 66.14, 65.24, 62.87, 46.48 (d, J = 64.7 Hz), 42.25 (d, J = 65.9 Hz). ESI-MS calculated for C4₂H₃₇BrNO₄P₂: m/z (%): 760.1376 (M+H⁺), found: 760.1373. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 7.0 min, minor enantiomer tr = 9.3 min. [α]_D²⁵= -18.4 (*c* = 0.25, CHCl₃).





Under conditions B: the product (+)-**3n** was obtained as a white solid (63.0 mg, 83% yield) with 14:1 dr and 97% *ee.* mp: 205-206 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 9.2 min, minor enantiomer tr = 6.8 min. $[\alpha]_D^{25} = +18.4$ (c = 0.25, CHCl₃).



15. Synthesis of (-)-30 and (+)-30.

Under conditions A: The reaction of alkene **1a** (42.8 mg, 0.1 mmol) and glycine imino ester **2o** (55.2 mg, 0.2 mmol), after a flash column chromatography (DCM: MeOH = 10:1) afforded the product (-)-**3o** as a white solid (53.2 mg, 84% yield) with 18:1 dr and 98% *ee*. mp: 95-96 °C. ¹H NMR (300 MHz, CDCl₃) δ 9.96 (s, 1H), 7.75-7.66 (m, 4H), 7.49-7.31 (m, 14H), 7.22-7.16 (m, 6H), 4.51-4.44 (m, 2H), 3.83-3.77 (m, 1H), 3.65-3.56 (m, 1H), 3.33 (t, *J* = 10.5 Hz, 1H), 2.92 (s, 3H). ³¹P NMR (202 MHz, CDCl₃) δ 33.38 (dd, *J* = 93.8, 30.0 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 192.09, 168.53 (d, *J* = 4.6 Hz), 147.57, 135.76, 132.11 (d, *J* = 11.1 Hz), 131.62 (d, *J* = 9.1 Hz), 131.34 (d, *J* = 8.8 Hz), 130.62 (dd, *J* = 26.6, 8.8 Hz), 129.91, 129.09, 128.86 (dd, *J* = 11.4, 8.8 Hz), 128.45 (dd, *J* = 18.6, 11.4 Hz), 119.51, 115.66, 65.38, 63.25, 51.31, 46.83 (d, *J* = 64.9 Hz), 42.31 (d, *J* = 64.7 Hz). ESI-MS calculated for C₃₇H₃₃NNaO₅P₂: m/z (%): 656.1726 (M+Na⁺), found: 656.1733. Enantiomeric excess was determined by HPLC with a

Chiralpak IB column (hexanes: 2-propanol = 65:35 to 50:50, 0.8 mL/min, 230 nm); major enantiomer tr = 12.9 min, minor enantiomer tr = 58.9 min. $[\alpha]_D^{25}$ = -12.4 (*c* = 0.25, CHCl₃).



Under conditions B: the product (+)-**30** was obtained as a white solid (57.6 mg, 91% yield) with 24:1 dr and 97% *ee.* mp: 105-106 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IB column (hexanes: 2-propanol = 65:35 to 50:50, 0.8 mL/min, 230 nm); major enantiomer tr = 57.1 min, minor enantiomer tr = 10.6 min. $[\alpha]_D^{25} = +21.6$ (*c* = 0.25, CHCl₃).



16. Synthesis of (-)-4 and (+)-4.

The solution of compound (-)-**3a** (68.3 mg, 0.1 mmol) in THF(2 mL) was stirred at -50 $^{\circ}$ C in a sealed tube. Subsequently, DIBAL-H (0.5 mmol) was added to the above solution. Then the reaction was determined by TLC analysis. After the (-)-**3a** was consumed completely, the reaction mixture was quenched by the addition of NH₄Cl aq. and diluted with EtOAc. The organic layer was separated, and the aqueous layer was extracted twice with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, concentrated. Then the crude product was then purified by flash column

chromatography on silica gel (DCM: MeOH = 10:1) afforded the product (-)-**4** as a white solid (44.6 mg, 68% yield) with 98% *ee*. mp: 266-267 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.85-7.80 (m, 2H), 7.56-7.52 (m, 3H), 7.46-7.19 (m, 15H), 7.14-7.09 (m, 4H), 4.35-4.29 (m, 1H), 3.95-3.88 (m, 1H), 3.73-3.65 (m, 2H), 3.48-3.43 (m, 2H), 3.24-3.13 (m, 1H). ³¹P NMR (162 MHz, CDCl₃) δ 35.57 (d, *J* = 29.8 Hz), 33.28 (d, *J* = 29.8 Hz). ¹³C NMR (101 MHz, CDCl₃) δ 140.35, 131.81, 131.41 (d, *J* = 20.2 Hz), 130.50 (d, *J* = 8.7 Hz), 130.35-130.08 (m), 129.69, 128.93, 128.81, 128.78-128.58 (m), 128.32 (d, *J* = 11.6 Hz), 125.15, 121.50, 67.44, 64.12, 61.58, 48.35 (d, *J* = 65.0 Hz), 41.73 (d, *J* = 66.5 Hz). ESI-MS calculated for C₃₇H₃₃NNaO₅P₂: m/z (%): 656.1726 (M+Na⁺), found: 656.1733. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 9.6 min, minor enantiomer tr = 17.0 min. [α]_D²⁵ = -52.8 (*c* = 0.25, CHCl₃).





The product (+)-4 was obtained as a white solid (49.9 mg, 76% yield) with 97% *ee.* mp: 245-246 °C. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 16.7 min, minor enantiomer tr = 10.0 min. $[\alpha]_D^{25} = +48.8$ (*c* = 0.25, CHCl₃).



17. Synthesis of (-)-5 and (+)-5.

The solution of compound (-)-3a (68.3 mg, 0.1 mmol) and K₂CO₃ (6.0 eq) in DMF (2 mL) was stirred at rt in a sealed tube. Subsequently, MeI (2.0 eq) was added to the above solution. Then the reaction was determined by TLC analysis. After the (-)-3a was consumed completely, the reaction mixture was quenched by the addition of NaCl aq. and the aqueous layer was extracted three or more times with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, concentrated. Then the crude product was then purified by flash column chromatography on silica gel (DCM: MeOH = 10:1) afforded the product (-)-5 as a white solid (66.9 mg, 96% yield) with 98% ee. mp: 65-66 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.66-7.61 (m, 2H), 7.48-7.39 (m, 7H), 7.35-7.26 (m, 5H), 7.21-7.13 (m, 6H), 7.04-6.97 (m, 4H), 3.88-3.77 (m, 2H), 3.69-3.62 (m, 1H), 3.54-3.47 (m, 1H), 2.90 (s, 3H), 2.13 (s, 3H). ³¹P NMR (162 MHz, CDCl₃) & 34.52 (dd, J = 416.8, 34.6 Hz), 30.27 (dd, J = 673.2, 34.7 Hz). ¹³C NMR (101 MHz, CDCl₃) δ 168.54 (d, J = 5.0 Hz), 140.02 (d, J = 3.1 Hz), 132.76 (d, J = 9.7 Hz), 131.88, 131.60,131.43, 131.32 (d, J = 3.2 Hz), 131.22, 130.94, 130.80 (d, J = 8.9 Hz), 128.46 (dd, J =17.0, 5.7 Hz), 128.00 (d, J = 11.9 Hz), 121.54, 77.30 (d, J = 3.1 Hz), 70.07, 69.66, 51.02 (d, J = 3.1 Hz), 42.35 (dd, J = 148.2, 66.0 Hz), 38.83 (d, J = 3.6 Hz). ESI-MS calculated for C₃₇H₃₄BrNNaO₄P₂: m/z (%): 720.1039 (M+Na⁺), found: 720.1031. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm; major enantiomer tr = 13.7 min, minor enantiomer tr = 48.7 min. $[\alpha]_D^{25} = -14.9$ (*c* = 0.25, CHCl₃).



The product (+)-5 was obtained as a white solid (64.8 mg, 93% yield) with 99% *ee*. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 49.4 min, minor enantiomer tr = 13.9 min. $[\alpha]_D^{25} = +15.6$ (*c* = 0.25, CHCl₃).



18. Synthesis of (-)-6 and (+)-6.

The solution of compound (-)-**3a** (68.3 mg, 0.1 mmol) in PhMe (2 mL) was stirred at 0 °C in a sealed tube. Subsequently, BH₃ • THF (0.5 mmol) was added to the above solution. Then the reaction was determined by TLC analysis. After the (-)-**3a** was consumed completely, the reaction mixture was quenched by the addition of NaCl aq. and the aqueous layer was extracted twice with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, concentrated. Then the crude product was then purified by flash column chromatography on silica gel (DCM: MeOH = 10:1) afforded the product (-)-**6** as a white solid (68.3 mg, 98% yield) with 94% *ee*.¹H NMR (400 MHz, CDCl₃) δ 7.78-7.74 (m, 2H), 7.54-7.30 (m, 16H), 7.26-7.10 (m, 6H), 5.87 (t, *J* = 10.0

Hz, 1H), 4.53-4.41 (m, 1H), 4.32-4.23 (m, 1H), 3.91-3.82 (m, 1H), 3.44-3.38 (m, 1H), 2.91 (s, 3H). ³¹P NMR (162 MHz, CDCl₃) δ 33.06 (dd, J = 349.2, 27.7 Hz). ¹³C NMR (101 MHz, CDCl₃) δ 164.84 (d, J = 4.6 Hz), 135.25 (d, J = 3.2 Hz), 132.48 (d, J = 9.4 Hz), 132.04 (s), 131.83, 131.46 (d, J = 9.1 Hz), 130.81, 130.52 (d, J = 7.7 Hz), 130.27 (s), 129.04 (t, J = 9.9 Hz), 128.83 (d, J = 2.9 Hz), 128.71 (d, J = 2.9 Hz), 123.19, 77.20, 69.71 (d, J = 17.0 Hz), 51.70, 44.73 (d, J = 64.7 Hz), 38.74 (d, J = 65.7 Hz). ESI-MS calculated for C₃₆H₃₅BBrNnaO₄P₂: m/z (%): 720.1210 (M+Na⁺), found: 720.1207. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 60:40, 0.8 mL/min, 230 nm); major enantiomer tr = 28.1 min, minor enantiomer tr = 13.3 min. [α]p²⁵ = -32.2 (c = 0.25, CHCl₃).



19. Synthesis of methyl (2*S*,3*S*,4*S*,5*S*)-5-(4-bromophenyl)-4-(diphenylphosphanyl)-3-(diphenylphosphoryl)-1-methylpyrrolidine-2-carboxylate (**7**).



The reaction of (-)-**4a** (0.29 mmol, 200 mg) in THF (5.3 ml) was stirred at rt. Subsequently, $(Me_2HSi)_2O$ (0.33 ml, 6.0 equiv) and $Ti(O^iPr)_4$ (0.37 ml, 4.6 equiv) were added to the above solution. The solution was reacted at 65 °C for 12 h. Then the reaction was determined by TLC analysis. After the substrate was consumed

completely, the reaction mixture was then purified by flash column chromatography on silica gel (PE: EA = 4:1 to 1:1) afforded the product **7** as white sollid (138 mg, 70% yield) with 97% *ee*. Mp = 88-89 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.78-7.74 (m, 2H), 7.50-7.38 (m, 5H), 7.33-7.24 (m, 7H), 7.22-7.15 (m, 5H), 7.14-7.06 (m, 5H), 3.77 (m, 1H), 3.46-3.34 (m, 1H), 3.27 (m, 1H), 3.17 (m, 1H), 2.95 (s, 3H), 2.15 (s, 3H). ³¹P NMR (202 MHz, CDCl₃) δ 30.29 (d, *J* = 24.9 Hz), -1.04 (d, *J* = 24.8 Hz). ¹³C NMR (126 MHz, CDCl₃) δ 169.30 (d, *J* = 5.0 Hz),140.67 (d, *J* = 5.5 Hz), 135.07 (d, *J* = 21.2 Hz), 133.56 (d, *J* = 20.2 Hz), 131.84 (d, *J* = 8.8 Hz), 131.27 (d, *J* = 8.7 Hz), 130.97 (d, *J* = 10.0 Hz), 129.84, 128.95, 128.33 (dd, *J* = 6.6, 3.5 Hz), 128.14 (d, *J* = 11.5 Hz), 128.42, 121.16, 74.90 (d, *J* = 20.8 Hz), 69.09 (d, *J* = 2.1 Hz), 51.09, 44.37 (dd, *J* = 66.8, 20.5 Hz), 41.35 (d, *J* = 16.0 Hz), 39.38. ESI-MS calculated for C₃₇H₃₄BrNNaO₃P₂: m/z (%): 704.1090 (M+Na⁺), found: 704.1082. Enantiomeric excess was determined by HPLC with a Chiralpak IA column (hexanes: 2-propanol = 65:35-45:55-65:35, 0.8 mL/min, 230 nm); major enantiomer tr = 15.1 min, minor enantiomer tr = 57.2 min. [α]_D²⁵ = -74.7 (*c* = 0.25, CHCl₃).





S30



20. Synthesis of S-(2,2,2-trifluoroethyl) (2*R*,3*R*)-3-hydroxy-2,3-diphenylpropanethioate (**10**).



The reaction of ligand (–)-**3a** (10 mol%, 19.5 mg) and DIPEA (10.0 eq.) in ^{*i*}PrCN (2 ml) was stirred at 0 °C. Subsequently, (2,2,2-trifluoroethyl)-S-2-phenylethanethioate (140.4 mg, 0.6 mmol) and SiCl₄ (1.5 eq.) were added to the above solution. After 15 min, PhCHO (0.3 mmol) was added to the above solution. Stirred for overnight, SiCl₄ (1.5 eq.) was added to the above solution. Then the reaction was determined by TLC analysis. After the substrate was consumed completely, the reaction mixture was quenched by the addition of NaHCO₃ aq. and diluted with EtOAc. The organic layer was separated, and the aqueous layer was extracted twice with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, concentrated. Then the crude product

was then purified by flash column chromatography on silica gel (PE: EA = 10:1) afforded the product **10** as liquid (66.3 mg, 65% yield) with 91:9 dr and 36% *ee*. ¹H NMR (400 MHz, CDCl₃) δ 7.36-7.32 (m, 5H), 7.29-7.25 (m, 5H), 5.34 (d, J = 7.6 Hz, 1H), 4.06 (d, J = 7.6 Hz, 1H), 3.44-3.34 (m, 2H), 2.34 (s, 1H). ¹⁹F NMR (282 MHz, CDCl₃) δ -66.36. ¹³C NMR (101 MHz, CDCl₃) δ 195.38, 140.26, 133.59, 129.38, 128.84, 128.46, 128.34, 128.19, 126.61, 124.37 (J_{C-F} = 277.1 Hz), 74.95, 68.15, 30.63 (q, J = 34.3 Hz). ESI-MS calculated for C₁₇H1₅F₃NaO₂S: m/z (%): 363.0637 (M+Na⁺), found: 363.0637. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (hexanes: 2-propanol = 90:10, 0.8 mL/min, 230 nm); major enantiomer tr = 11.8 min, minor enantiomer tr = 22.0 min. [α]_D²⁵ = +2.8 (c = 0.25, CHCl₃).



21. Synthesis of (1*S*,4*R*)-5-butyl-7-methyl-1,3-diphenyl-4-(3,4,5-trimethoxyphenyl)-3,4-dihydro-1*H*-furo[3,4-d][1,2]oxazine (**13**).



The reaction of AuCl(Me₂S) (5 mol%) and ligand (-)-**3a** (5.5 mol%) in DCM (2 ml) was stirred at rt. After stirred for 1h, AgSbF₆ (5 mol%) was added above solution and continue stirred for 10 min in -50 °C. Subsequently, 2-(1-alkynl)-alk-2-en-1-one **11** (0.1 mol) and nitrone **12** (2.0 equiv) were added to the above solution. After 48 h, then the reaction was determined by TLC analysis. After the substrate was consumed completely, the crude product was then purified by flash column chromatography on

silica gel (PE: EA = 10:1) afforded the product **13** as liquid (37.4 mg, 73% yield) with >20:1 dr and 77% *ee*. Mp = 38-39 °C. ¹H NMR (300 MHz, CDCl₃) δ 7.56-7.53 (m, 2H), 7.41-7.39 (m, 3H), 7.24-7.19 (m, 2H), 7.06 (d, *J* = 7.6 Hz, 2H), 6.92 (t, *J* = 7.3 Hz, 1H), 6.49 (s, 2H), 5.97 (d, *J* = 0.8 Hz, 1H), 5.63 (s, 1H), 3.79 (s, 3H), 3.69 (s, 6H), 2.50-2.45 (m, 2H), 1.82 (s, 3H), 1.53-1.45 (m, 2H), 1.32-1.22 (m, 2H), 0.84 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 152.21, 148.45, 148.07, 143.26, 137.80, 137.17, 134.52, 129.14, 128.90, 128.39, 128.36, 122.12, 117.83, 116.85, 116.79, 106.45, 78.57, 62.50, 60.61, 55.82, 29.91, 26.24, 22.19, 13.62, 12.38. ESI-MS calculated for C₃₂H₃₅NNaO₅: m/z (%): 536.2407 (M+Na⁺), found: 536.2410. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (hexanes: 2-propanol = 90:10, 0.8 mL/min, 254 nm); major enantiomer tr = 7.8 min, minor enantiomer tr = 9.5 min. [α]_D²⁵ = +88.6 (*c* = 0.25, CHCl₃).



5. References

(1) (a) A. Z. González, D. Benitez, E. Tkatchouk, W. A. Goddard and F. D. Toste, *J. Am. Chem. Soc.* 2011, **133**, 5500-5507. (b) I. Alonso, B. Trillo, F. López, S. Montserrat, G. Ujaque, L. Castedo, A. Lledós and J. L. Mascareñas, *J. Am. Chem. Soc.* 2009, **131**, 13020-13030. (c) A. Z. González and F. D. Toste, *Org. Lett.* 2010, **12**, 200-203.

(2) M. Narsireddy and Y. Yamamoto, J. Org. Chem. 2008, 73, 9698-9709.

(3) (a) S. Cabrera, R. G. Arrayás, J. C. Carretero, *J. Am. Chem. Soc*, 2005, **127**, 16394.
(b) C. Nájera, M. de Gracia Retamosa, J. M. Sansano, *Org. Lett.* 2007, **9**, 4025. (c) A. López-Pérez, J. Adrio, J. C. Carretero, *J. Am. Chem. Soc*, 2008, **130**, 10084.

6. ¹H, ³¹P, ¹³C NMR and HPLC Spectra

¹H NMR (400 MHz, CDCl₃), ³¹P NMR (162 MHz, CDCl₃) and ¹³C NMR (101 MHz,

CDCl₃) of 3a





 1H NMR (500 MHz, CDCl_3), ^{31}P NMR (202 MHz, CDCl_3) and ^{13}C NMR (126 MHz,

CDCl₃) of **3b**

 8. 6066

 8. 5910

 8. 5910

 8. 5910

 8. 5910

 8. 5910

 8. 5910

 8. 5910

 8. 5910

 8. 5910

 8. 5910

 8. 5910

 8. 5910

 8. 5910

 8. 5910

 77. 70

 77. 70

 77. 70

 77. 75115

 77. 75115

 77. 4896

 77. 47466

 77. 47466

 77. 47030

 77. 47466

 77. 47466

 77. 47030

 77. 47466

 77. 47466

 77. 47466

 77. 47466

 77. 47466

 77. 47466

 77. 47466

 77. 2009

 77. 2014

 77. 2014

 77. 1235

 77. 1235

 77. 1235

 77. 1235

 77. 1235

 77. 11042

 77. 1042

 77. 1042

 77.







¹H NMR (400 MHz, CDCl₃), ³¹P NMR (162 MHz, CDCl₃) and ¹³C NMR (126 MHz,

CDCl₃) of **3c**





¹H NMR (400 MHz, CDCl₃), ¹⁹F NMR (282 MHz, CDCl₃), ³¹P NMR (162 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) of **3d**





S40



¹H NMR (400 MHz, CDCl₃), ³¹P NMR (162 MHz, CDCl₃) and ¹³C NMR (126 MHz,

CDCl₃) of 3e





S42

¹H NMR (400 MHz, CDCl₃), ¹⁹F NMR (282 MHz, CDCl₃), ³¹P NMR (101 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) of **3f**







¹H NMR (400 MHz, CDCl₃), ³¹P NMR (202 MHz, CDCl₃) and ¹³C NMR (126 MHz,

CDCl₃) of 3g





¹H NMR (500 MHz, CDCl₃), ³¹P NMR (202 MHz, CDCl₃) and ¹³C NMR (126 MHz,

CDCl₃) of 3h







¹H NMR (500 MHz, CDCl₃), ³¹P NMR (202 MHz, CDCl₃) and ¹³C NMR (126 MHz,

CDCl₃) of 3i





¹H NMR (500 MHz, CDCl₃), ³¹P NMR (202 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) of **3**j





S50

¹H NMR (500 MHz, CDCl₃), ³¹P NMR (202 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) of **3**k





¹H NMR (300 MHz, CDCl₃), ³¹P NMR (122 MHz, CDCl₃) and ¹³C NMR (126 MHz,

CDCl₃) of 31







¹H NMR (500 MHz, CDCl₃), ³¹P NMR (202 MHz, CDCl₃) and ¹³C NMR (126 MHz,

CDCl₃) of 3m





¹H NMR (400 MHz, CDCl₃), ³¹P NMR (162 MHz, CDCl₃) and ¹³C NMR (101 MHz,

$CDCl_3$) of 3n







¹**H NMR** (300 MHz, CDCl₃), ³¹**P NMR** (202 MHz, CDCl₃) and ¹³**C NMR** (126 MHz, CDCl₃) of **30**





¹H NMR (400 MHz, CDCl₃), ³¹P NMR (162 MHz, CDCl₃) and ¹³C NMR (101 MHz,

CDCl₃) of 4





¹H NMR (400 MHz, CDCl₃), ³¹P NMR (162 MHz, CDCl₃) and ¹³C NMR (101 MHz, CDCl₃) of **5**





¹H NMR (400 MHz, CDCl₃), ³¹P NMR (162 MHz, CDCl₃) and ¹³C NMR (101 MHz,

CDCl₃) of 6





¹H NMR (500 MHz, CDCl₃), ³¹P NMR (202 MHz, CDCl₃) and ¹³C NMR (126 MHz, CDCl₃) of **7**





¹H NMR (400 MHz, CDCl₃), ¹⁹F NMR (282 MHz, CDCl₃) and ¹³C NMR (101 MHz, CDCl₃) of **10**











